

## Epilepsy Therapy Screening Program (ETSP)

**Preclinical testing program to identify new therapies to address the unmet medical needs in epilepsy**


- Established in 1975 and known for 40 years as the Anticonvulsant program; tested over 30K compounds; contributed to 11 marketed antiseizure drugs
- New ETSP name reflects focus on drug resistant epilepsy and expansion into areas of disease prevention and modification
- Open to small molecules, biologics, natural products and devices
- No cost to participant, participant IP protected, and confidentiality maintained

Contact: Brian Klein,  
[brian.klein@nih.gov](mailto:brian.klein@nih.gov)



## Preclinical Screening Platform for Pain (PSPP)

**Provides a platform to identify and profile non-addictive, non-opioid therapeutics for pain**



PSPP is open to academic, industry and government asset owners worldwide

Contact: Smriti Iyengar,  
[smriti.iyengar@nih.gov](mailto:smriti.iyengar@nih.gov)



## Initial Translational Efforts (IGNITE)

**Grant funding to build on innovative basic science findings and initiate preclinical drug discovery and development**

- Neurotherapeutic Agent Characterization and In vivo efficacy studies (PAR-21-122)
- Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (PAR-21-123)
- Assay Development and Neurotherapeutic Agent identification (PAR-21-124)

R61/R33 up to 3 years. Up to 750k for the entire project

Contact: Rebecca Roof,  
[Rebecca.roof@nih.gov](mailto:Rebecca.roof@nih.gov)




## NINDS Division of Translational Research (DTR)

*Mission: To accelerate basic research findings toward patient use for neurological disorders and stroke by providing funding, expertise, and resources to the research community.*

DTR offers a variety of programs that support the design, implementation, and management of research activities critical to translational challenges in the treatment of neurological disease.

<https://www.ninds.nih.gov/current-research/research-funded-ninds/translational-research>

Join our Listserv:



## Biomarker Initiatives: Neurological Disorders and Pain

- Discovery of Biomarkers, Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (HEAL): RFA-NS-22-050
- Development of Biomarkers for Neurological/Neuromuscular Disease: PAR-22-089
- Analytical Validation of a Candidate Biomarker for Neurological Disease: PAR-21-056 (U01), PAR-21-057 (U44)
- Clinical Validation of a Candidate Biomarker for Neurological Disease: PAR-21-058 (U01), PAR-21-059 (U44)



Contact: Carol Taylor-Burds (NINDS), [carol.taylor-burds@nih.gov](mailto:carol.taylor-burds@nih.gov),  
Ram Arudchandran (HEAL), [Ramchandran.arudchandran@nih.gov](mailto:Ramchandran.arudchandran@nih.gov)

## BPN – Small Molecules

**Cooperative agreement and SBIR Fast-Track award programs support Small Molecules drug discovery & development**

- Customized infrastructure, expertise, contract access, and grant funding (combined up to \$12M/project)
- Grant and contract support: medicinal chemistry, compound database, PK, toxicology, drug manufacturing and formulation, phase I clinical trials
- PAR-20-122 (UG3/UH3) up to 5 years
- PAR-20-111 (SBIR) up to 5 years



Contact: Charles Cywin, [charles.cywin@nih.gov](mailto:charles.cywin@nih.gov)

## BPN – Biologics

### Cooperative agreement and SBIR Fast-Track award programs support Biologics drug discovery & development

- Includes optimization and early development activities, IND-enabling studies, assembly of IND application
- Grant and contract support as needed for example pharmacokinetic studies, toxicology (GLP and non-GLP), safety testing plus access to experts in therapeutics development through a consulting service
- PAR-21-163 (UG3/UH3) up to 5 years
- PAR-21-233 (U44 SBIR) up to 5 years



Contact: Chris Boshoff, [chris.boshoff@nih.gov](mailto:chris.boshoff@nih.gov)

## Ultra-Rare Gene-based Therapies (URGenT)

### Funding/resources to advance gene-based therapies from late-stage pre-clinical development into first-in-human clinical testing

PAR-20-030 (U01, Clinical Trial Optional)

- Accelerates development of a clinical candidate with biological rationale and proof of concepts towards an IND filing & clinical trial initiation with access to CRO/GMO, SMEs and with a budget associated with the award

PAR-22-028


- Provides investigators with mechanism to access CRO/GMO, SMEs for nonclinical therapeutic



Contact: Chris Boshoff, [chris.boshoff@nih.gov](mailto:chris.boshoff@nih.gov)

## Pain Therapeutics Development Program (PTDP)

Goal: Accelerate development of novel, non-opioid, non-addictive analgesics



- Phased (UG3/UH3) research grant
- Therapeutics can be biologics or small molecules
- Grant features access to biopharma-experienced consultants and NIH-sponsored Contract Research Organizations
- End goals include IND submission, Phase I Clinical Trial and formation of partnerships to progress candidate therapeutic through clinical testing
- Eligible institutions include academic institutions & small businesses

Contact: Mary Ann Pellymouter,  
[mary.pellymouter@nih.gov](mailto:mary.pellymouter@nih.gov)

Neuroscience Conference 2022

## Therapeutic and Diagnostic Devices & BRAIN

### Cooperative agreements including SBIR Fast-Track for development validation, verification, and early clinical studies.

Scope of this program supports projects that are either:

- Very close to the "final system" with similar manufacturing process as the device to be marketed or studied in a larger clinical trial following the completion, OR
- Require early feasibility clinical data to inform the final device design or manufacturing processes

TND: RFA-NS-21-021 (UG3/UH3), RFA-NS021-022 (SBIR)

BRAIN Initiative: RFA-NS-21-023 (UG3/UH3), RFA-NS-21-024 (UH3), NOT-NS-22-052

Blueprint MedTech: PAR-21-315 (UG3/UH3), PAR-21-282

Contact: Nick Langhals,  
[nick.langhals@nih.gov](mailto:nick.langhals@nih.gov)



## Small Business Program

### NIH small business programs (SBIR/STTR) are congressionally mandated funds to encourage research/development leading to commercialization

- More than \$70M in annual set-aside funds for small business
- Includes therapeutics, neurotech, diagnostics and research tools
- Awardees have access to assistance programs and investor show case opportunities
- Omnibus PAR-22-176 (SBIR), PA-22-178 (STTR), and other specific announcements
- Contact us to learn more!



**SBIR · STTR**  
America's Seed Fund

Contact: Emily Caporello, [Emily.caporello@nih.gov](mailto:Emily.caporello@nih.gov)

## Office of the Neural Exposome and Toxicology (ONETOX)

### Provides resources to advance knowledge of internal and external exposures that affect nervous system health, leads research related to chemical threats

Contact: David Jett [jett@ninds.nih.gov](mailto:jett@ninds.nih.gov)

#### Neural Exposome

- Databases of neurotoxins and gene-environment interactions
- Grant funding for research into how exogenous, endogenous, and behavioral factors impact brain health

David Jett, Ph.D.: [jett@nih.gov](mailto:jett@nih.gov)



#### Countermeasures Against Chemical Threats (CounterACT)

- Grant funding for basic and preclinical translational research on chemical threats to national security
  - PAR-23-027 (R01) Early-stage and New Investigators are encouraged
  - PAR-22-209 (UG3/UH3), PAR-20-253 (R21) translational research

Shardell Spriggs, Ph.D.: [shardell.spriggs@nih.gov](mailto:shardell.spriggs@nih.gov)



#### Chemical Safety

- Resources for drug safety in translational research and management of biohazards and dual use research concerns (DURC)

Shardell Spriggs, Ph.D.: [shardell.spriggs@nih.gov](mailto:shardell.spriggs@nih.gov)

